| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Ophthalmologic System |
Recent Updates
Recently added Catalysts
Kodiak Sciences Inc$41.25
-1.17 (-2.76%)
C 49Pipeline Score Fair Value Biotech · Clinical
Market Cap
2.27 B
EPS
-4.17
P/E Ratio
-
Value Trade
31.10 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
48.55 M
Operating CF
-40.01 M
Total Assets
306.01 M
Total Liabilities
193.91 M
Equity
112.10 M
D/E Ratio
12,345
-3.39 %
Week
-22.67 %
1 Month
38.49 %
3 Month
86.18 %
6 Month
-55.74 %
5 Year
262.3 %
All Time
Cash Data
Cash Position
169.53 M
Monthly Burn
13.34 M
Runway
10.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
463.80 K
52 Week Range
3.26 - 47.84
% held by Insiders
7.49 %
% held by Institutions
96.3 %
Enterprise Value
2.25 B
Total Shares
62.55 M
Short %
18.36 %
Float Shares
31.21 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Kodiak Sciences Inc
412Total events
8Upcoming
69Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
◆Topline ReadoutKSI-501Clinical Data
Subscribe to view catalyst details
TBD
◆Topline ReadoutZenkudaFiledClinical Data
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-02-07 | KSI-101 | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-02-07 | KSI-101 | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-02-07 | KSI-101 | Phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
C49
Pipeline Score $1.7B
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored2.4x
rNPV / MCap Top 73%
Small Cap (rank 247 of 912)
Percentile RankKodiak Sciences Inc carries a moderate pipeline score (49/100), with $3.4B risk-adjusted pipeline value, led by Tarcocimab tedromer in Wet Age-related Macular Degeneration (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KSI-301 Small molecule | Macular Edema | Phase 3 | NCT04592419 | 44% | $1.0B | COMPLETED | 568 | - | - | Jan 19, 2023 | - | Jun 26, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Zenkuda | diabetic retinopathy | Phase 3 | 2026-05-07 | 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001); 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001); ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001); low cataract adverse event rate (2% per arm) Read More | Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Read More | |
Zenkuda | diabetic retinopathy | Phase 3 | 2026-05-07 | 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001); 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001); ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001); low cataract adverse event rate (2% per arm) Read More | Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Read More | |
Zenkuda | diabetic retinopathy | Phase 3 | 2026-05-07 | 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p<0.0001); 85% risk reduction in the key secondary endpoint of development of sight threatening complications (2.4% with Zenkuda vs 15.8% with sham, p=0.0001); ≥3-step improvement in DRSS (13.7% with Zenkuda vs 0% with sham, p<0.0001); low cataract adverse event rate (2% per arm) Read More | Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in KOD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
KOD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
KODKodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
Kodiak Sciences Inc. will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026. CEO Victor Perlroth, M.D., will lead the presentation, showcasing the company's commitment to developing transformative retinal therapeutics. A live webcast will be available for those unable to attend in person.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
Kodiak Sciences reported positive Phase 3 results for Zenkuda, demonstrating significant efficacy in diabetic retinopathy. The company is advancing its late-stage pipeline with multiple readouts expected in 2026, including studies for wet AMD and macular edema. Despite a net loss of $58.2 million in Q1 2026, Kodiak's cash position supports operations into 2027.
Read more →KODKodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Kodiak Sciences announced it will present clinical data for KSI-101 at the upcoming American Uveitis Society and ARVO meetings. The results from a tertiary care cohort are consistent with previous studies, indicating the drug's potential across diverse patient populations. The company is advancing its pipeline, including KSI-101, KSI-102, and KSI-103, aimed at treating retinal diseases.
Read more →KOD▲ +12.3%on this news
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Kodiak Sciences reported positive Phase 3 topline results for Zenkuda in diabetic retinopathy and highlighted advancements in its pipeline programs. The company completed enrollment in the Phase 3 DAYBREAK study for wet AMD and continues to develop KSI-101 and other candidates. Despite a net loss increase, Kodiak's cash position supports its operations into 2027.
Read more →KOD▲ +74.8%on this newsshared move
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
Kodiak Sciences announced positive topline results from the GLOW2 Phase 3 study, showing Zenkuda's superiority over sham in treating diabetic retinopathy. The study included a broader patient population and demonstrated a significant improvement in DRSS scores. Zenkuda was well-tolerated, with no serious ocular adverse events reported, supporting its potential as a long-lasting treatment option.
Read more →KOD▼ -6.9%on this news
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
Kodiak Sciences announced the presentation of final results from the Phase 1b APEX study for KSI-101 at the Angiogenesis 2026 meeting. The data indicate significant visual and anatomical improvements in patients with macular edema secondary to inflammation. These findings bolster confidence in KSI-101's potential as a leading therapy for MESI, with ongoing Phase 3 studies actively enrolling participants.
Read more →KOD▲ +8.1%on this news
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences Inc. has announced that its senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will highlight the company's precommercial efforts and its portfolio of late-stage clinical programs targeting retinal diseases. Kodiak is aiming to address leading causes of blindness with its innovative therapeutics, including candidates in Phase 3 studies. Live webcasting of the event will be available on Kodiak's website.
Read more →KODKodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences Inc. has successfully closed a public offering of 8 million common shares, raising approximately $184 million. This amount includes shares sold through the underwriters' full exercise of their additional purchase option. The funds will strengthen Kodiak's financial position as the company progresses through critical Phase 3 topline readouts for its late-stage clinical assets. The offering was conducted through a previously filed registration statement with the SEC.
Read more →KODKodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing...
Kodiak Sciences, a biotechnology company focused on retina therapies, has announced the pricing of an upsized public offering of approximately 6.96 million shares at $23.00 per share. This offering is anticipated to raise around $160 million before expenses. The transaction is subject to customary closing conditions and is expected to close on or about December 18, 2025. Additionally, Kodiak has granted underwriters a 30-day option to purchase additional shares.
Read more →KODKodiak Sciences Announces Proposed Public Offering of Common Stock
Kodiak Sciences Inc. has announced a proposed public offering of 6 million shares of common stock, with an option for underwriters to purchase an additional 900,000 shares. The offering is subject to market conditions and is intended to support the company's development of transformative retinal therapeutics. The shares will be sold under a previously filed shelf registration statement.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
Kodiak Sciences reported strong business highlights and financial results for Q3 2025, showcasing positive momentum in its late-stage programs. The company anticipates continued progress into 2026 with multiple Phase 3 data readouts and a planned BLA filing. Despite a net loss increase and rising R&D expenses, the firm remains optimistic about its pipeline advancements.
Read more →KOD▼ -6.8%on this newsshared move
Kodiak Sciences to Present at Upcoming Investor Conferences
Kodiak Sciences Inc. will present at upcoming investor conferences, highlighting its commitment to developing innovative retinal therapeutics. CEO Victor Perlroth will lead the presentations, which will be available via live webcast. The company is advancing three late-stage clinical programs targeting retinal vascular diseases and macular edema.
Read more →KODFollow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
Kodiak Sciences has reported promising follow-up data from the APEX study of KSI-101, an investigational therapy for macular edema secondary to inflammation (MESI). The data indicates that over 90% of patients achieved absence of retinal fluid by week 20, with significant improvements in visual acuity. The company aims to advance KSI-101 into Phase 3 studies, potentially establishing it as a cornerstone therapy for MESI.
Read more →KODNew data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Kodiak Sciences presented new data from the APEX study of KSI-101 at the Retina Society meeting. The study demonstrated significant improvements in visual acuity and retinal thickness in patients with macular edema secondary to inflammation (MESI). KSI-101, a bispecific therapy targeting IL-6 and VEGF, showed promising results and a favorable safety profile, paving the way for its advancement into Phase 3 studies.
Read more →KODKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
Kodiak Sciences Inc. announced its participation in two upcoming scientific conferences where Phase 1b APEX data on KSI-101 for macular edema secondary to inflammation (MESI) will be presented. The conferences include the 25th EURetina Congress in Paris and the Retina Society 58th Annual Scientific Meeting in Chicago. KSI-101 has shown promising results in improving visual outcomes for MESI patients and is advancing to Phase 3 trials.
Read more →KODKodiak Sciences to Present at American Chemical Society Fall 2025
Kodiak Sciences Inc. will present its glaucoma pipeline at the ACS Fall 2025 Meeting. The company is developing dual-mechanism therapies using its ABCD platform to address optic neuropathy. Additionally, Kodiak is innovating clinical trial designs with its VETi program, which employs AI to improve testing accuracy and frequency.
Read more →KOD▲ +16.5%on this newsshared move
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
Kodiak Sciences reported its second quarter 2025 financial results, highlighting significant advancements in its late-stage clinical assets, including KSI-101 and tarcocimab. The company showcased promising data from its clinical trials, particularly for KSI-101 in treating macular edema. Despite a net loss of $54.3 million, Kodiak's cash reserves are projected to sustain operations into 2026.
Read more →KODKodiak Sciences to Host Investor R&D Day on July 16, 2025
Kodiak Sciences Inc. will host an investor R&D Day on July 16, 2025, featuring presentations on its late-phase clinical assets. The event aims to provide insights from Kodiak's leadership and industry experts. A live webcast will be available, and a recording will be accessible shortly after the event.
Read more →KODKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
Kodiak Sciences will present highlights of KSI-101 at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro. KSI-101 is a bispecific biologic targeting IL-6 and VEGF for treating macular edema secondary to inflammation. The presentation aims to address current treatment limitations and showcase promising clinical data.
Read more →KODKodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Kodiak Sciences Inc. will present at the 2025 Jefferies Global Healthcare Conference on June 5, 2025. CEO Victor Perlroth, M.D., will lead the presentation in New York City. A live webcast will be available on Kodiak's website, allowing for replay after the event. The company is focused on developing therapeutics for retinal diseases.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results Palo Alto, CA —
Kodiak Sciences, Inc. reported its financial results for Q1 2025, indicating a net loss of $57.5 million. The company highlighted its pipeline of three promising Phase 3 assets, with an upcoming Investor R&D Update scheduled for July 16, 2025. Significant points include updates on the Phase 3 GLOW2 study for diabetic retinopathy and the DAYBREAK study for wet AMD, along with financial stability supported by available cash of $138.9 million.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In...
Kodiak Sciences Inc. reported its financial results for Q1 2025, highlighting a net loss of $57.5 million and a cash position of $138.9 million. The company is focused on advancing its three Phase 3 assets, with topline data expected in 2026. An Investor R&D Update is scheduled for July 16, 2025, to discuss further developments.
Read more →KODKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. announced its participation in the ARVO 2025 Annual Meeting, presenting seven scientific posters focused on its novel ABC platform and related therapeutic developments. The presentations will cover areas such as ocular inflammatory diseases and geographic atrophy, emphasizing innovative treatments that target underlying cytokine interactions. Notably, KSI-101, currently in clinical trials for macular edema, shows promising results regarding its safety and efficacy. The event aims to demonstrate Kodiak's commitment to addressing significant unmet needs in retinal disease therapies.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Palo Alto, CA —
Kodiak Sciences reported its fourth quarter and full year 2024 financial results, highlighting significant advancements in its clinical pipeline, including Phase 3 studies for tarcocimab and KSI-501. The company aims to address significant unmet needs in retinal therapies, with KSI-101 targeting inflammation-related macular edema. Financially, while Kodiak recorded a net loss of $44.1 million, it showed improved metrics from the previous year. With a cash reserve of $168.1 million, Kodiak believes it can sustain operations into 2026.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended...
Kodiak Sciences reported its financial results for Q4 and full year 2024, highlighting significant progress in its clinical trials, particularly for tarcocimab and KSI-501. The company is focused on addressing unmet needs in retinal diseases and anticipates key data releases in 2026. Despite a net loss of $44.1 million, Kodiak's cash position remains strong, supporting operations into 2026.
Read more →KODKodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in...
Kodiak Sciences Inc. has successfully completed enrollment in its GLOW2 Phase 3 clinical trial for tarcocimab tedromer, targeting diabetic retinopathy patients. Over 250 patients have been randomized, exceeding initial enrollment goals, and topline clinical data is expected to be announced in Q1 2026. The trial design is similar to the GLOW1 study, which showed strong results in treating diabetic retinopathy. The success of GLOW2 could pave the way for regulatory approval and market introduction of tarcocimab.
Read more →KODKodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. will present its innovative glaucoma treatment program at the Glaucoma 360 New Horizons Forum on February 7, 2025. The company's novel "duet" therapy, leveraging its Antibody Biopolymer Conjugate Drug platform, targets neuroinflammation while lowering intraocular pressure, presenting a comprehensive approach to glaucoma. This presentation emphasizes the need for next-generation therapies to significantly improve patient outcomes for glaucoma, a major cause of irreversible blindness worldwide.
Read more →KODKodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. (Nasdaq: KOD) announced that its CEO, Victor Perlroth, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company focuses on transformative therapeutics for retinal diseases, with ongoing clinical trials for its lead product tarcocimab and other investigational medicines. Kodiak is advancing its ABC Platform™ to enhance drug-development capabilities and address various retinal diseases.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. "In the third...
Kodiak Sciences reported its Q3 2024 financial results, highlighting significant advancements in its clinical programs, including the enrollment of patients in Phase 3 studies for tarcocimab and KSI-501. The company hosted an Investor R&D Day to showcase new clinical data and discuss future strategies. Despite a net loss of $43.9 million, Kodiak maintains a strong cash position to support operations through 2026.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results Palo Alto, CA —
Kodiak Sciences provided an update on its business and financial performance for Q3 2024, showcasing key advancements in its clinical programs. The company has initiated patient enrollment in Phase 3 studies for tarcocimab targeting diabetic retinopathy and wet AMD. Notably, data indicates that tarcocimab benefits from a significantly extended ocular half-life. Furthermore, the KSI-101 program is poised to address medical gaps in macular edema secondary to inflammation. The upcoming readouts from these studies are anticipated in mid-2025.
Read more →KOD▲ +8.5%on this newsshared move
Kodiak Sciences to Participate in Upcoming Investor Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. announced its participation in upcoming investor conferences, where management will present details and engage in one-on-one meetings. The company is focused on developing transformative therapeutics for retinal diseases and has a robust pipeline, including two late-stage clinical programs derived from its ABCD Platform. Their lead investigational medicine, tarcocimab, is undergoing Phase 3 trials for diabetic retinopathy and wet AMD. The company aims to address unmet needs in retinal therapy with innovative approaches including their biopolymer technology.
Read more →KODKodiak Sciences to Present at Innovate Retina 2024 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. (Nasdaq: KOD) announced its participation in Innovate Retina 2024, scheduled for October 17, 2024, in Chicago, Illinois. The company is focused on developing therapeutics for retinal diseases, utilizing its proprietary ABCD Platform™. Currently, Kodiak has three clinical programs, with its lead drug, tarcocimab, in two Phase 3 trials. Kodiak aims to address significant unmet needs in treating retinal vascular diseases.
Read more →KODKodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be...
Kodiak Sciences Inc. (Nasdaq: KOD) is hosting an Investor R&D Day today in New York, scheduled from 10:30 am to 12:30 pm ET. The event includes presentations from Kodiak's leadership and notable retina specialist key opinion leaders. Participants can access the webcast and will have the opportunity to view replay and presentation materials on Kodiak's website.
Read more →KODKodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. is set to host an Investor R&D Day on September 23, 2024, in New York City, aimed at engaging with financial analysts and institutional investors. The event will feature discussions on Kodiak's clinical pipeline, including advancements in their ABCD platform technology, and provide insights into the durability of their treatments. CEO Victor Perlroth expressed enthusiasm for sharing key insights regarding their investigational medicines and optimizing the clinical studies based on past learnings. The presentation will also include contributions from prominent retina specialists.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results Palo Alto, CA —
Kodiak Sciences reported robust business highlights and financial results for Q2 2024. Their clinical programs, including tarcocimab and KSI-501, are advancing, with enrollment ongoing in multiple Phase 3 studies. The company is also enhancing its leadership team to bolster its research and commercial efforts. Future plans include an Investor Day to update stakeholders on continued progress and strategy.
Read more →KODKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. "Our three clinical ...
Kodiak Sciences reported significant progress in its clinical programs and leadership changes during Q2 2024. The company is actively enrolling patients in pivotal Phase 3 studies for its investigational drugs, tarcocimab and KSI-501, aimed at treating retinal diseases. Despite a net loss of $45.1 million, Kodiak's cash reserves are projected to support operations until 2026.
Read more →KODKodiak Sciences to Present at Upcoming Investor and Clinical Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. (Nasdaq: KOD) has announced upcoming presentations at investor and clinical conferences, highlighting its commitment to developing innovative treatments for retinal diseases. The company will showcase its clinical pipeline on June 8 at the Clinical Trials at the Summit 2024 meeting in Park City, Utah. Kodiak is advancing three clinical programs, including its lead candidate tarcocimab for retinal vascular diseases, which address critical health issues such as diabetic retinopathy and age-related macular degeneration.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. "We continue to...
Kodiak Sciences reported significant operational advancements and financial results for Q1 2024, highlighting progress in its clinical programs, particularly with tarcocimab and KSI-501. The company is on track to initiate multiple Phase 3 studies and has successfully presented data at the ARVO 2024 Annual Meeting. Despite a net loss of $43 million, Kodiak's cash reserves are expected to support operations through 2026.
Read more →KODKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results Palo Alto, CA —
Kodiak Sciences reported strong operational advancements and financial results for Q1 2024, highlighting progress in their clinical studies for tarcocimab, KSI-501, and KSI-101. The company is on track to activate pivotal Phase 3 studies for retinal diseases, aiming to enhance treatment options in wet AMD and diabetic retinopathy. Financially, Kodiak ended the quarter with $245.9 million in cash, sufficient to fund operations into 2026, despite a net loss of $43.0 million. The firm reflects optimism following successful early-phase study results, which could position it competitively in the market.
Read more →KOD▲ +6.1%on this newsshared move
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences has announced the treatment of the first patients in its Phase 3 GLOW2 study for tarcocimab tedromer in diabetic retinopathy. This study aims to evaluate the efficacy and safety of the drug in treatment-naïve patients using extended dosing intervals. The promising results from the earlier GLOW1 study, which demonstrated significant improvements and risk reductions in diabetic retinopathy, bolster the importance of this new trial. Successful outcomes could facilitate marketing authorization for tarcocimab, furthering Kodiak's commitment to advancing therapies for retinal diseases.
Read more →KODKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety...
Kodiak Sciences announced significant advancements in its retinal disease pipeline during presentations at the ARVO 2024 Annual Meeting. Highlights included strong clinical data for tarcocimab, demonstrating its efficacy and safety profile in treating diabetic retinopathy. The company also showcased promising first-in-human results for KSI-501, a bispecific protein aimed at treating diabetic macular edema. These developments underscore Kodiak's commitment to enhancing treatment options for retinal diseases through its innovative ABC Platform.
Read more →KOD▼ -29.4%on this news· ran to -43% by day 3
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market
Kodiak Sciences has announced recent business highlights, including financial results for 2023 and advancements in its clinical programs. The company is progressing three late-stage assets toward Phase 3 trials, specifically targeting diabetic retinopathy and wet AMD. Notably, the GLOW2 Phase 3 study of tarcocimab is actively recruiting patients and builds on prior success with GLOW1. Kodiak believes that its growing portfolio positions it well within the competitive landscape of retinal treatments.
Read more →KOD▼ -29.4%on this news· ran to -43% by day 3
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results Three clinical programs present diversified opportunities in and outside the existing anti-VEGF market and are being progressed toward Phase 3 value...
Kodiak Sciences has reported significant advancements in its clinical programs, with three assets progressing towards Phase 3 trials. The GLOW2 study for diabetic retinopathy is actively recruiting, while KSI-501's Phase 1 results indicate safety and efficacy. Despite a net loss of $59.5 million in Q4 2023, the company maintains a strong cash position to support operations into 2026.
Read more →KOD▲ +16%on this news· ran to -27% by day 3shared move
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences (Nasdaq: KOD) has announced it will report its fourth quarter and full-year 2023 financial results on March 28, 2024. In conjunction with the report, the company will host a conference call to discuss business highlights and updates. Kodiak is focused on treating retinal diseases with innovative therapeutics, including lead investigational drugs like tarcocimab and KSI-501. As the company progresses with its late-stage clinical programs, it also highlights potential risks associated with forward-looking statements regarding its developments.
Read more →KOD▼ -8.6%on this news
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences announced that it will present the first-time results of its KSI-501ABC Phase 1 study at the upcoming Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is a bispecific therapeutic candidate targeting both IL-6 mediated inflammation and VEGF-mediated angiogenesis, aimed at treating diabetic macular edema. Early findings suggest the data may support future clinical development of KSI-501, with presentations scheduled for February 3, 2024. Kodiak is focused on bringing innovative retinal therapeutics to market to tackle high-prevalence retinal diseases.
Read more →KODKodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. (Nasdaq: KOD) will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will highlight the company's commitment to developing therapeutics for retinal diseases and showcase its innovative antibody biopolymer conjugate platform. A live webcast will be available on Kodiak's website, allowing stakeholders to follow the event remotely.
Read more →KOD▼ -7.4%on this news
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. will present at the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, at 3:25 p.m. ET. The company focuses on developing therapeutics for retinal diseases and will showcase its innovative antibody biopolymer conjugate platform. A live webcast of the presentation will be accessible on the company’s website, ensuring that stakeholders can follow Kodiak's updates and research progress.
Read more →KOD▲ +6.7%on this news· ran to +38% by day 3
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023. "We have three ...
Kodiak Sciences reported its Q3 2023 financial results, highlighting progress in its retinal disease pipeline, including promising data from the GLOW phase 3 study of tarcocimab. The company plans to reboot the tarcocimab program and is advancing its KSI-501 clinical program. Despite a net loss of $50 million, the company remains optimistic about its future prospects.
Read more →KOD▲ +6.7%on this news· ran to +38% by day 3
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Inc. reported its Q3 2023 financial results and highlighted key business developments, including a promising outcome from the pivotal GLOW study for tarcocimab. The GLOW study showed a significant improvement in diabetic retinopathy patients, meeting all primary and secondary endpoints. Kodiak's current pipeline includes three retinal disease candidates, providing a strong outlook for future growth. However, the company reported a net loss of $50 million for the quarter, although its cash reserves remain robust at $345.7 million.
Read more →KOD▼ -13.6%on this news
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission Primary endpoint and all key secondary endpoints met with high statistical significance in GLOW study. With 6-month dosing of all patients,...
Kodiak Sciences Inc. announced the successful results of its Phase 3 GLOW study, which evaluated tarcocimab tedromer for treating moderately severe to severe diabetic retinopathy. The study met its primary endpoint, demonstrating a 29-fold increased response rate in patients treated with tarcocimab compared to sham. All key secondary endpoints were also met, indicating a substantial reduction in the development of sight-threatening complications. Following discussions with the FDA, Kodiak plans to pursue a single Biologics License Application for tarcocimab across multiple retinal indications.
Read more →KOD▲ +6.2%on this news· ran to +46% by day 1shared move
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING Kodiak Sciences Inc (NASDAQ: KOD) today announced that data from tarcocimab tedromer will be presented during the annual meeting of the American...
Kodiak Sciences Inc has announced the presentation of data from the Phase 3 GLOW study at the American Academy of Ophthalmology's annual meeting. The study focuses on tarcocimab tedromer for patients with non-proliferative diabetic retinopathy. It will highlight the efficacy of a novel treatment regimen involving every six-month dosing without loading doses. The results aim to address a prevalent complication of diabetes that can lead to severe vision impairment.
Read more →KODKodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. announced its participation in the 56th Annual Scientific Meeting of The Retina Society, scheduled from October 11-14, 2023. The company will present results from three Phase 3 studies for its investigational drug, tarcocimab tedromer (KSI-301), addressing conditions such as wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Notably, this meeting marks the first public presentation of primary results from the Phase 3 DAYLIGHT study. Such presentations indicate Kodiak's ongoing commitment to innovative retinal therapeutics.
Read more →KODKodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York on September 13, 2023. The presentation will focus on the company’s commitment to developing therapeutics for high-prevalence retinal diseases. A live webcast of the event will be available on the company's website. Kodiak aims to bring innovative treatments to market, utilizing its proprietary ABC Platform™ for drug development.
Read more →KODNew one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion Tarcocimab demonstrated strong durability, matched efficacy and comparable safety versus aflibercept in a head-to-head comparative pivotal trial over ...
Kodiak Sciences Inc. announced positive one-year results from its pivotal BEACON trial for tarcocimab tedromer, showcasing its efficacy and durability in treating macular edema due to retinal vein occlusion. The study revealed that tarcocimab matched the efficacy of aflibercept while requiring significantly fewer injections, with 50% of patients needing none after initial treatment. The results enhance confidence in the ABC Platform and set the stage for future analysis of additional studies. Kodiak plans to release more data from the GLOW study for diabetic retinopathy in the fourth quarter.
Read more →KOD▼ -6.8%on this news· ran to -20% by day 3
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences reported its Q2 2023 financial results, highlighting setbacks in the Phase 3 GLEAM and GLIMMER studies for tarcocimab due to increased cataract rates. Despite these challenges, the company noted positive outcomes in the DAYLIGHT study and plans to advance the KSI-501 clinical program. Kodiak ended the quarter with $378.7 million in cash.
Read more →KOD▼ -6.8%on this news· ran to -20% by day 3
Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences reported Q2 2023 results revealing significant setbacks in the Phase 3 GLEAM and GLIMMER studies of tarcocimab for diabetic macular edema, which failed to meet primary efficacy endpoints due to an unexpected increase in cataract events. Meanwhile, encouraging findings from the DAYLIGHT study reaffirmed tarcocimab's potential. The company also highlighted advancements in the KSI-501 clinical program, which has completed enrollment for its Phase 1 study and may offer improved outcomes based on learnings from the earlier program. Overall, financial results indicated a net loss of $80.2 million for the quarter.
Read more →KOD▼ -45.9%on this news· ran to -60% by day 3
Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program Kodiak Sciences Inc. (NASDAQ: KOD) announced today topline results from three Phase 3 studies of tarcocimab tedromer, a novel antibody biopolymer...
Kodiak Sciences announced topline results from Phase 3 studies of its drug tarcocimab tedromer for treating neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME). While the DAYLIGHT study showed non-inferior visual acuity gains compared to aflibercept, the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints and revealed a concerning increase in cataracts among treated patients. As a result, Kodiak is discontinuing the development of the tarcocimab program but continues to advance its KSI-501 project. Detailed study results will be presented at an upcoming scientific meeting.
Read more →KODKodiak Sciences to Present at Upcoming Investor Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. is set to present at several investor conferences, highlighting its ongoing commitment to transformative therapeutics for retinal diseases. The company is known for its innovative antibody biopolymer conjugate platform, which is central to its development of therapies like tarcocimab tedromer. This investigational medicine targets significant retinal vascular diseases and is supported by multiple clinical studies. Phase 3 data for tarcocimab is expected in the third quarter of 2023, marking a critical milestone for the company's pipeline.
Read more →KOD▲ +12.6%on this news· ran to +24% by day 1
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences reported its financial results for Q1 2023, highlighting a reduced net loss compared to the same quarter last year. The company is approaching key Phase 3 study readouts for its investigational therapy tarcocimab, targeting various retinal diseases. The successful outcomes of these studies are critical, as they aim to provide extended treatment intervals for patients. Additionally, Kodiak has launched a new Phase 1 study for a bispecific therapy, KSI-501, indicating ongoing expansion in their clinical pipeline.
Read more →KODKodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. (Nasdaq: KOD) announced presentations regarding its clinical and research pipeline at the ARVO 2023 Annual Meeting, scheduled for April 23-27 in New Orleans. The presentations will cover key investigational medicines, including data on the lead product tarcocimab tedromer, which aims to treat retinal diseases. Kodiak's pipeline includes Phase 3 studies and a Phase 1 study for KSI-501, a new bispecific therapy. The company is committed to advancing innovative therapeutics for high prevalence retinal conditions.
Read more →KOD▼ -12.3%on this news· ran to -23% by day 3
Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. has initiated a Phase 1 clinical study for KSI-501, an investigational bispecific antibody biopolymer conjugate targeting VEGF and IL-6, in patients with diabetic macular edema. The study aims to evaluate the safety and establish a maximum tolerated dose for the treatment. KSI-501 is noted for its potential to offer improved therapeutic benefits compared to existing treatments. The company plans to expand the study to other diseases after dose escalation is complete.
Read more →KODKodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences announced its financial results for the fourth quarter and full year 2022, highlighting progress in its tarcocimab pivotal program and pipeline development. The company is set to report topline data from four Phase 3 studies in the third quarter of 2023. Although Kodiak ended the year with $478.9 million in cash, it also reported a net loss of $70.4 million for Q4 2022, reflecting ongoing investment in research and development. The firm aims to advance its dual-targeted product candidate KSI-501 and enhance its digital health offerings in ophthalmology.
Read more →KODKodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences announced its upcoming presentation at the Angiogenesis, Exudation, and Degeneration 2023 Virtual Meeting, where it will present clinical data from its investigational therapy KSI-301 and provide updates on its Antibody Biopolymer Conjugate development programs. CEO Victor Perlroth expressed optimism about the ongoing clinical trials and the anticipated readouts for KSI-301. The presentation will also cover KSI-501, which has cleared an IND and is poised to begin Phase 1 studies soon, potentially serving as a first-in-class treatment for retinal diseases.
Read more →KOD▲ +9.4%on this news
Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
Kodiak Sciences Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The company is focused on developing transformative therapeutics for retinal diseases, utilizing their proprietary ABC Platform™. Their lead product candidate, tarcocimab tedromer, is aimed at treating conditions such as wet age-related macular degeneration. Kodiak's innovative approach may significantly impact the treatment landscape for blindness-related diseases.
Read more →KODKodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference Kodiak Sciences Inc. (NASDAQ: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 16, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will
Read more →KODKodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA November 9, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr
Read more →KODKodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Sept. 7, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will
Read more →KODKodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO) Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Aug. 18, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that results from the
Read more →KODKodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA August 9, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tre
Read more →KOD▲ +14.1%on this newsshared move
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion Kodiak Sciences Inc. (Nasdaq: KOD) today announced that its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab), its novel antibody...
PALO ALTO, Calif. , Aug. 8, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ) today announced that its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab), its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline
Read more →KOD▲ +6.3%on this news· ran to +36% by day 3shared move
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Aug. 5, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed
Read more →KODKodiak Sciences to Present at the Jefferies Global Healthcare Conference PALO ALTO, Calif., May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and...
PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Je
Read more →KOD▲ +11.8%on this news
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
BASEL, Switzerland and PALO ALTO, Calif. , May 19, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza annou
Read more →KODKodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights Palo Alto, CA May 10, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat
Read more →KODKodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , April 29, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations o
Read more →KODKodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights Palo Alto, CA March 1, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therap
Read more →KOD▼ -80.4%on this news
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3...
PALO ALTO, Calif. , Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b /3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel an
Read more →KODKodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Feb. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed
Read more →KOD▲ +5.5%on this news
Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Jan. 3, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will p
Read more →KODKodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Dec. 16, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed
Read more →KODKodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA November 9, 2021 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr
Read more →KODKodiak Sciences to Present at Upcoming Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high-prevalence retinal diseases, today announced that management will p
Read more →KODSummary of the LTPIP Overview Below is an overview of the LTPIP, which is intended as a summary only and is qualified in its entirety by the full text of the LTPIP attached to this proxy statement as Appendix 1. Plan Ter
Summary of the LTPIP Below is an overview of the LTPIP, which is intended as a summary only and is qualified in its entirety by the full text of the LTPIP attached to this proxy statement as Appendix 1. Plan Terms Details Eligible Employees Employees at Grade Level 10 and ab
Read more →KODKodiak Sciences Announces New Long-Term Performance Incentive Plan Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share Palo Alto, CA  
Kodiak Sciences Announces New Long-Term Performance Incentive Plan Pay for Performance: Program Aligns Incentives to Significant Value Creation through Share Price Milestones of $200 to $800 per Share Palo Alto, CA September 1, 2021 Kodiak Sciences Inc. (Nasdaq: KOD), a biophar
Read more →KODKodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Aug. 31, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will
Read more →KODKodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA —
Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA August 9, 2021 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tre
Read more →KODKodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights Palo Alto, CA - May 10, 2021 - Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to tr
Read more →KODKodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights Palo Alto, CA - March 1, 2021 - Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative th
Read more →KODKodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Feb. 13, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced promising 1-year dura
Read more →KODKodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Feb. 2, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a presentation of
Read more →KODKodiak Sciences to Present at the J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will p
Read more →KODKodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 20, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its pr
Read more →KODKodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an und
Read more →KODKodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that recruitment has
Read more →KODKodiak Sciences Announces Proposed Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has commenced
Read more →KODKodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Nov. 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that a pre-recorded p
Read more →KODKodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces Third Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA - November 9, 2020 - Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Read more →KODKodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...
PALO ALTO, Calif. , Oct. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that the first patient
Read more →KODKodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces Second Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA - August 10, 2020 - Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics t
Read more →KODKodiak Sciences to Host R&D Webcast to Review Recent Data from the Ongoing Phase 1b Study of KSI-301 and Highlight KSI-301 Clinical Development Progress Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , July 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a R&D Webcast for investors a
Read more →KODKodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases today announced promising additional safety, efficacy and durabi
Read more →KODKodiak Sciences Announces Upcoming Presentation of KSI-301 Clinical Study Data at American Society of Retina Specialists (ASRS) 2020 Virtual Annual Meeting and R&D Webinar Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of
Read more →KODKodiak Sciences to Present at Upcoming Conferences Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , May 28, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present at the following up
Read more →KODKodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights Palo Alto, CA - May 11, 2020 - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retina
Read more →KODKodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the virtual Bank of A
Read more →KODKodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020 Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tue
Read more →KODKodiak Sciences Appoints Charles Bancroft to Board of Directors Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , April 2, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of
Read more →KODKodiak and Kodiak Sciences Trademarks Registered to Kodiak Sciences Inc. for Its Exclusive Use Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , March 24, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that the company received full registration of
Read more →KODKodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., March 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to tre
Read more →KODKodiak Sciences Announces Additional Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation, and Degeneration 2020 Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Feb. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced promising safety, efficacy and durability data f
Read more →KODKodiak Sciences Announces Upcoming Presentation of Additional KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2020 Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Feb. 5, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that a presentation of additional clinical study
Read more →KODKodiak Sciences to Present at 38th Annual J.P. Morgan Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Jan. 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced today that management will present a company overview
Read more →KODKodiak Sciences Appoints Taiyin Yang, Ph.D., to Board of Directors Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 19, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Taiyin Yang, Ph.D., to its b
Read more →KODKodiak Sciences Announces Closing of $317.4 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the closing of its previously announced underwri
Read more →KODKodiak Sciences Announces Pricing of $276.0 Million Public Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 3, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the pricing of an underwritten public offering o
Read more →KODKodiak Sciences Announces Proposed Offering of Common Stock Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has commenced an underwritten public off
Read more →KODKodiak Sciences to Present at the Evercore ISI HealthCONx Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Evercore ISI
Read more →KODKodiak Sciences Announces Sale of Future Royalties on KSI-301 for $225 Million to Baker Bros. Advisors Kodiak Sciences Inc. (Nasdaq: KOD) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net ...
PALO ALTO, Calif. , Dec. 2, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ) today announced that the Company has entered into a funding agreement to sell a capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million . KSI-301 is Kodiak's
Read more →KODKodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Third Quarter 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., Nov. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high
Read more →KODKodiak Sciences to Report Third Quarter 2019 Results and Host Business Highlights Webcast on November 12, 2019 Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Nov. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will report third quarter 2019 results o
Read more →KODKodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301 Kodiak Sciences Inc. (Nasdaq: KOD) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic ...
PALO ALTO, Calif. , Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ) will host an R&D Day in San Francisco to highlight significant progress in the development of its lead therapeutic candidate KSI-301. The R&D event, including a live video stream, will be held o
Read more →KODKodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Americ
Kodiak Sciences Announces Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the American Academy of Ophthalmology Annual Meeting Retina Subspecial
Read more →KODKodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that the first patients have been treated in the DAZZ
Read more →KODKodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that Charles C. Wykoff , M.D., Ph.D., will prese
Read more →KODKodiak Sciences Announces Emerging Durability Data from Ongoing Phase 1b Study of KSI-301 in Wet AMD Patients at The Retina Society Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Sept. 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced emerging durability data in patients with wet
Read more →KODKodiak Sciences to Release Durability Data from Clinical Development Program of KSI-301 for wet AMD at The Retina Society Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that updated data from the clinical developmen
Read more →KODKodiak Sciences to Present at the Morgan Stanley Global Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Sept. 6, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will participate in the Morgan
Read more →KODKodiak Sciences Announces Upcoming Presentations at EURETINA Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Sept. 4, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be made
Read more →KODKodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights Palo Alto, CA
Kodiak Sciences Announces Second Quarter 2019 Financial Results and Recent Business Highlights Palo Alto, CA - August 14, 2019 - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence re
Read more →KODKodiak Sciences to Present at Wedbush PacGrow Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Wedbush PacG
Read more →KODKodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion,
Kodiak Sciences Announces Positive Interim Data from Ongoing Phase 1b Clinical Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Wet AMD, Diabetic Eye Disease, and Retinal Vein Occlusion, at the American Society of Retina Specialists 2019 Annual M
Read more →KODKodiak Sciences Announces Upcoming Presentation at American Society of Retina Specialists (ASRS) 2019 Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , July 24, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that data from the ongoing KSI-301 clinical stu
Read more →KODKodiak Sciences to Present at the Jefferies 2019 Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , May 30, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Jefferies 20
Read more →KODKodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights PALO ALTO, Calif., May 15, 2019 /PRNewswire/ - Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-p
Read more →KODKodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference 2019 Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , May 9, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Bank of Ameri
Read more →KODKodiak Sciences Announces Presentations at ARVO 2019 Annual Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , April 25, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that presentations on its research will be mad
Read more →KODKodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights PALO ALTO, Calif., March 28, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to tre
Read more →KODKodiak Sciences to Present at the Barclays Global Healthcare Conference Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , March 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the Barclays Gl
Read more →KODKodiak Sciences Announces Upcoming Presentation of KSI-301 12-Week Phase 1a Study Data at Angiogenesis, Exudation, and Degeneration 2019 Meeting Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Feb. 8, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that a presentation on its investigational thera
Read more →KODKodiak Sciences Added to Russell 2000®, 3000® and Microcap® Indexes Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 24, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it has been added to the Russell 2000®, 30
Read more →KODKodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence...
PALO ALTO, Calif. , Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported last visit (twelve-week) data from its Phase 1a
Read more →KODKodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights
Kodiak Sciences Announces Third Quarter 2018 Financial Results and Recent Business Highlights PALO ALTO, Calif., Nov. 16, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high
Read more →KODKodiak Sciences Inc. Announces Closing of Initial Public Offering Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock...
PALO ALTO, Calif. , Oct. 10, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD ) today announced the closing on October 9 , 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of $10.00 per share. The gross proceeds to Kodiak, bef
Read more →KODKodiak Sciences Inc. Announces Pricing of Initial Public Offering Kodiak Sciences Inc. ( Kodiak ) today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the...
PALO ALTO, Calif. , Oct. 3, 2018 /PRNewswire/ -- Kodiak Sciences Inc. ("Kodiak") today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $10.00 per share. In addition, Kodiak has granted the underwriters a 30-
Read more →KODKodiak Sciences Inc. Announces Launch of Initial Public Offering Kodiak Sciences Inc. ( Kodiak ) today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an...
PALO ALTO, Calif. , Sept. 24, 2018 /PRNewswire/ -- Kodiak Sciences Inc. ("Kodiak") today announced that it has launched an initial public offering of 9,000,000 shares of its common stock at an anticipated initial offering price between $13.00 and $15.00 per share pursuant to a re
Read more →KODKodiak Sciences Expands Leadership with Industry Veterans Including Appointment of Jason Ehrlich, M.D., Ph.D., as Chief Medical Officer and Chief Development Officer Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases,...
PALO ALTO, Calif. , Sept. 17, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the appointment of Jason S. Ehrlich , M.D., Ph.D., as Chief Medical
Read more →KODKodiak Sciences Files Registration Statement for Proposed Initial Public Offering Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating ...
PALO ALTO, Calif. , Sept. 7, 2018 /PRNewswire/ -- Kodiak Sciences Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares
Read more →KODKodiak Sciences Announces Completion of Enrollment in the Company's Phase 1 Safety and Tolerability Study in Patients with Retinal Disease Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases,...
PALO ALTO, Calif. , Aug. 31, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that enrollment of patients in the company's phase 1 safety and tole
Read more →KODKodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases,...
PALO ALTO, Calif. , July 18, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a clinical stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the appointments of Bassil I. Dahiyat , Ph.D., Robert A. Profusek ,
Read more →KODKodiak Sciences Inc. Announces Presentations at ARVO 2018 Annual Meeting Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases,...
PALO ALTO, Calif. , April 27, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced that presentations on its research will be made at the Associati
Read more →KODKodiak Sciences Completes $33 Million Mezzanine Private Financing Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases,...
PALO ALTO, Calif. , April 26, 2018 /PRNewswire/ -- Kodiak Sciences Inc., a development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, today announced the completion of a $33 million mezzanine private financing of c
Read more →KODKodiak Sciences Inc. and Lonza Announce Agreements for the Development and Manufacture of Medicines for the Treatment of Retinal Disease Lonza, a global leader in biological and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel ...
BASEL , Switzerland and PALO ALTO, Calif. , Feb. 8, 2016 /PRNewswire/ -- Lonza, a global leader in biological and chemical manufacturing, and Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, announced
Read more →KODKodiak Sciences Inc. Closes Series B Financing to Fuel Retina Pipeline Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, announced today the...
PALO ALTO, Calif. , Jan. 12, 2016 /PRNewswire/ -- Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, announced today the closing of a $34 million Series B financing. The round was led by a U.S.-based li
Read more →Competitive Position
How KOD ranks across every disease it competes inCompetitive Position is a premium feature
See how KOD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial